Intermittent and continuous imatinib in a human GIST xenograft model carrying<i>KIT</i>exon 17 resistance mutation D816H
Mona-Elisabeth Revheim(Oslo University Hospital), Therese Seierstad(Oslo University Hospital), Eirik Malinen(Norwegian Computing Center), Øyvind S. Bruland(University of Oslo), Alexandr Kristian(Oslo University Hospital), Jeanne-Marie Berner(Oslo University Hospital), Heikki Joensuu(Orion Corporation (Finland)), Ruth Holm(University of Aleppo)
Cited by 15
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k